Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10034MR)

This product GTTS-WQ10034MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10034MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3803MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ4328MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ7036MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ6146MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ10985MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ6746MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ12277MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1408MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACA125
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW